Respiratory syncytial virus (RSV), a common respiratory infection in children, has increasingly been identified as a leading cause of respiratory disease in the elderly.
GlobalData, a leading data and analytics company, in their latest report, ‘GlobalData (2019). RSV – Epidemiology Forecast Report to 2028, July 2019’, reveals that the elderly group at risk for RSV is one of the fastest growing RSV-prophylactic populations. GlobalData estimates that 5.01m adults lived in nursing homes in the seven major markets (7MM*) in 2018, with this figure set to rise by 24% over the next ten years to more than 6.2 million adults by 2028.
Topias Lemetyinen, Managing Epidemiologist for GlobalData, commented: “This growth is expected across the 7MM, predominantly driven by an aging population and the increased availability and access to long-term care in older age.’’
It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries. Currently, RSV has neither a known cure nor a vaccine; however, preventive measures such as prophylactic treatment can be taken to help mitigate the spread of the disease.
Topias concludes: “RSV is a major concern for the elderly population. RSV is considered to be a leading cause of pneumonia, which can lead to hospitalization and death. Ensuring that the elderly are treated with adequate prophylaxis will be a major consideration in their care in the future.”
*7MM = US, France, Germany, Italy, Spain, UK, and Japan